Sanofi SA
featured
Patent expirations on big-name drugs has resulted in modestly less spending on medicines in the U.S. for the first time in at least 55 years, a report showed Thursday.
» Read More.160x105.jpg?v=1366904651 "Fed Could Give Market a Safety Net")
More
-
FRANKFURT, May 3- Eli Lilly, the world's fourth-largest diabetes drugs maker, aims to have the widest range of anti diabetic drugs in order to win a larger slice in the growing market.
-
May 3- Scripps Networks Interactive Inc:. For a summary of rating and price target changes on U.S. companies: Reuters Eikon users, click on RCH/US Reuters 3000 Xtra users, double-click RCH/US Reuters Station users, click. 1568.
-
May 3- Scripps Networks Interactive Inc:. *RBC raises target price to $72 from $68; rating outperform. Reuters Station users, click. 1568.
-
May 3- Scripps Networks Interactive Inc:. *Wunderlich raises price target to $77 from $72; rating buy. Reuters Station users, click. 1568.
-
*Pfizer, Amgen, AstraZeneca among firms placing bets. LONDON, May 3- Is nanomedicine the next big thing? Three deals struck this year by privately held Bind Therapeutics, together worth nearly $1 billion if experiments are successful, highlight a new interest in using such tiny carriers to deliver drug payloads to specific locations in the body.
-
*Pfizer, Amgen, AstraZeneca among firms placing bets. LONDON, May 3- Is nanomedicine the next big thing? Three deals struck this year by privately held Bind Therapeutics, together worth nearly $1 billion if experiments are successful, highlight a new interest in using such tiny carriers to deliver drug payloads to specific locations in the body.
-
May 3- Scripps Networks Interactive Inc:. *MKM Partners raises target price to $80 from $70; rating buy. Reuters Station users, click. 1568.
-
*Deutsche Bank raises target price to 90 euros from 89 euros; rating buy. For a summary of rating actions and price target changes on European companies:. Reuters Station users, click. 1580.
-
May 3- Scripps Networks Interactive Inc:. *Nomura raises price target to $64 from $59; rating neutral. Reuters Station users, click. 1568.
-
The BNY Mellon index of leading American depositary receipts. Shire PLC said sales of its Fabry's disease treatment, which competes with Sanofi's Genzyme, fell 15 percent. The BNY Mellon index of leading European ADRs gained 0.3 percent, while the FTSEurofirst 300 index of top shares closed up 0.4 percent.
-
There's a lot of fear about Friday's jobs report. Bears are already saying this could be the report that finally forces the markets to take a breather.
-
U.S. stock index futures climbed Thursday as Wall Street cheered a better-than-expected jobless claims report and after the European Central Bank cut its key interest rate.
-
*S&P Capital IQ raises target price to 86 euros from 81 euros; rating buy. For a summary of rating and price target changes on U.S. companies: Reuters Eikon users, click on RCH/US Reuters 3000 Xtra users, double-click RCH/US Reuters Station users, click. 1568.
-
PARIS, May 2- Sanofi SA:.
-
LONDON, May 2- European shares were set to fall on Thursday, with concerns about the global economy's health and caution ahead of the European Central Bank's policy meeting prompting investors to trim their trading positions. A separate report from the Institute for Supply Management showed the manufacturing sector expanded only modestly in April.
-
Peugeot and U.S. peer General Motors GM.N are studying an alliance to market vans outside of Europe that would allow the French car maker to boost sales volumes and reap royalty revenues, according to Les Echos newspaper. FRANCE TELECOM France's industry minister said he had blocked Yahoo Inc's. Dailymotion is owned by France Telecom.
-
May 1- Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident.
-
May 1- Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident.
-
EUROPEAN COMPANIES BG GROUP PLC Q1 SIEMENS AG Q2 DEUTSCHE LUFTHANSA AG Q1 METRO AG Q1 SANOFI SA Q1 ORKLA ASA Q1 SWISS RE AG Q1 KONINKLIJKE DSM NV Q1 HUGO BOSS AG Q1 INFINEON TECHNOLOGIES AG Q2 REXEL SA Q1 STATOIL ASA Q1 SWISSCOM AG Q1 BEIERSDORF AG Q1 BRITISH SKY BROADCASTING GROUP Q3 INMARSAT PLC Q1 RANDGOLD RESOURCES LTD Q1 ROYAL DUTCH SHELL PLC Q1 SMITH& NEPHEW PLC Q1 VERBUND AG Q1 BAYERISCHE MOTOREN WERKE AG Q1 GRIFOLS SA Q1 COFINIMMO SA Q1 DANSKE BANK A/S Q1 SHIRE PLC Q1 VALLOUREC SA Q1 U.S.
-
COPENHAGEN, May 1- Denmark's Novo Nordisk could see the U.S. launch of its biggest drug hope, a new long-acting insulin, delayed until 2018 while it conducts more tests to satisfy regulators, it said on Wednesday.